729
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Gilead Sciences's recently active trials. Comparator arms are excluded.
- Fludarabine14 trials
- Cyclophosphamide14 trials
- Lenacapavir Tablet10 trials
- Lenacapavir Injection8 trials
- Zimberelimab8 trials
- Sacituzumab govitecan8 trials
Upcoming readouts
Next primary completion dates among Gilead Sciences's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Mar 2027Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adoles…Phase 2
- Jun 2027Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in …Phase 3
- Aug 2027A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed P…Phase 2
- Dec 2028Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With A…Phase 2
- Mar 2029Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virolo…Phase 3
- Mar 2029Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1…Phase 3
Top therapeutic areas
Conditions studied most often across Gilead Sciences's recently active trials.
- HIV-1-infection15 trials
- Pre-Exposure Prophylaxis of HIV Infection5 trials
- HIV Infections4 trials
- Primary Biliary Cholangitis3 trials
- Triple Negative Breast Cancer3 trials
- Advanced Solid Tumor3 trials
Gilead Sciences pipeline by phase
The main study drugs across 77 active trials Gilead Sciences leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 315 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Sacituzumab govitecan-hziy | 11 | 1 | Oct 2026 est. | NCT06486441 · NCT05840211 · NCT05382299 |
| Sacituzumab Govitecan-hziy (SG) | 4 | 2 | Mar 2027 est. | NCT05633654 · NCT05089734 · NCT05186974 |
| Axicabtagene Ciloleucel | 3 | — | Oct 2030 est. | NCT05605899 · NCT05371093 · NCT05041309 |
| Lenacapavir | 3 | 2 | Mar 2029 est. | NCT07683000 · NCT07682961 · NCT06532656 |
| Lenacapavir Injection | 3 | — | Sept 2028 est. | NCT07047716 · NCT06513312 · NCT06101342 |
| Bictegravir | 2 | — | — | NCT06333808 · NCT05502341 |
| ISL/LEN | 2 | — | — | NCT06630299 · NCT06630286 |
| Oral Lenacapavir (LEN) | 2 | — | — | NCT04994509 · NCT04925752 |
| Anitocabtagene Autoleucel | 1 | — | Jul 2028 est. | NCT06413498 |
| KITE-753 | 1 | 1 | May 2031 est. | NCT07479797 |
| Sacituzumab Govitecan (SG) | 1 | 1 | Oct 2029 est. | NCT06801834 |
| Seladelpar | 1 | 1 | Aug 2030 est. | NCT06051617 |
| Seladelpar 5 mg Capsule | 1 | — | Nov 2028 est. | NCT03301506 |
| Tenofovir DF | 1 | — | — | NCT01651403 |
| Zimberelimab | 1 | — | Jun 2028 est. | NCT05502237 |
Phase 216 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Denikitug | 3 | 3 | Dec 2028 est. | NCT07546812 · NCT07527858 · NCT05007782 |
| anitocabtagene-autoleucel | 2 | — | Dec 2026 est. | NCT05396885 · NCT04155749 |
| Domvanalimab | 2 | — | Mar 2027 est. | NCT06727565 · NCT05676931 |
| GS-3242 Tablet | 2 | 2 | Aug 2027 est. | NCT07708727 · NCT07645287 |
| Oral Lenacapavir | 2 | 1 | Mar 2027 est. | NCT06749054 · NCT04150068 |
| ATV | 1 | — | — | NCT02016924 |
| B/F/TAF (Adult Strength) | 1 | — | — | NCT02881320 |
| emvistegrast | 1 | — | — | NCT06290934 |
| ISL | 1 | — | — | NCT05052996 |
| KTE-X19 | 1 | — | Jul 2027 est. | NCT06253663 |
| Lenacapavir Tablet | 1 | — | — | NCT06101329 |
| Lepetegravir | 1 | — | Jan 2028 est. | NCT06544733 |
| TAF | 1 | — | — | NCT02932150 |
| Teropavimab | 1 | — | — | NCT05729568 |
| Tilpisertib Fosmecarbil | 1 | — | Jan 2027 est. | NCT06029972 |
| Zimberelimab (ZIM) | 1 | — | Sept 2029 est. | NCT05633667 |
Phase 115 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| KITE-363 | 2 | 1 | Jun 2029 est. | NCT07304154 · NCT07038447 |
| B/F/TAF | 1 | — | Mar 2028 est. | NCT07055451 |
| GS-0151 | 1 | — | Mar 2027 est. | NCT06902519 |
| GS-0201 | 1 | 1 | Sept 2028 est. | NCT06167317 |
| GS-0415 | 1 | 1 | Aug 2029 est. | NCT07719491 |
| GS-1206 | 1 | 1 | Sept 2029 est. | NCT07703878 |
| GS-2121 | 1 | 1 | Jun 2028 est. | NCT06532565 |
| GS-2426 | 1 | 1 | Jan 2029 est. | NCT07601243 |
| GS-4321 | 1 | 1 | Jan 2030 est. | NCT07096193 |
| GS-4528 | 1 | — | Oct 2026 est. | NCT05840224 |
| GS-4571 | 1 | 1 | Nov 2026 est. | NCT06562907 |
| GS-5319 | 1 | 1 | May 2028 est. | NCT07128303 |
| GS-9911 | 1 | — | Dec 2026 est. | NCT06082960 |
| INT2104 | 1 | — | Oct 2026 est. | NCT06539338 |
| KITE-197 | 1 | — | Nov 2026 est. | NCT06079164 |
Phase 41 drug
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| F/TAF (High Dose Tablet) | 1 | 1 | Mar 2034 est. | NCT06337032 |
Combination backbones Cyclophosphamide (1 trial). Established agents these trials combine with, listed separately from the drugs under study.
Derived from 77 active trials Gilead Sciences leads; 77 name an intervention, folding into 47 phased drugs. This is ComplyRx's reading of the registry, not Gilead Sciences's own pipeline disclosure.
Gilead Sciences trials
The 50 most significant of Gilead Sciences's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| INVISEA Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous TreatmentNCT06539338INT2104 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 10 est. | Oct 2026 |
| Study of GS-4528 in Adults With Solid TumorsNCT05840224GS-4528 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 182 est. | Oct 2026 |
| Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)NCT06562907GS-4571 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 134 est. | Nov 2026 |
| Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell LymphomaNCT06079164KITE-197 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 21 est. | Nov 2026 |
| Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentNCT04617522Sacituzumab Govitecan-hziy | Phase 1 | Locked · track to reveal | OngoingRecruiting | 30 est. | Dec 2026 |
| Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)NCT04639986Sacituzumab Govitecan-hziy | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 331 est. | Dec 2026 |
| iMMagine-1Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)NCT05396885anitocabtagene-autoleucel | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 136 est. | Dec 2026 |
| Study of GS-9911 With or Without Antibody Treatment for Adults With Solid TumorsNCT06082960GS-9911 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 45 est. | Dec 2026 |
| PALEKONAStudy of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisNCT06029972Tilpisertib Fosmecarbil | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 176 est. | Jan 2027 |
| Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and ChildrenNCT06749054Oral Lenacapavir | Phase 2 | Locked · track to reveal | OngoingRecruiting | 12 est. | Mar 2027 |
| EVOKE-02Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)NCT05186974Sacituzumab Govitecan-hziy (SG) | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 193 est. | Mar 2027 |
| VELOCITY-HNSCCStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01NCT06727565Domvanalimab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 39 est. | Mar 2027 |
| Study of GS-0151 in Participants With Rheumatoid ArthritisNCT06902519GS-0151 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 65 est. | Mar 2027 |
| ASCENT-J02Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsNCT05101096Sacituzumab Govitecan-hziy | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 135 est. | May 2027 |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654Sacituzumab govitecan-hziy (SG) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,514 est. | Jun 2027 |
| JKART-1Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaNCT06253663KTE-X19 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 25 est. | Jul 2027 |
| A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1NCT07645287GS-3242 Tablet | Phase 2 | Not yet scored | OngoingRecruiting | 175 est. | Aug 2027 |
| EDGE-LungStudy With Various Immunotherapy Treatments in Participants With Lung CancerNCT05676931Domvanalimab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 400 est. | Dec 2027 |
| WONDERS1Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedNCT06544733Lepetegravir | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 675 est. | Jan 2028 |
| Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVNCT07055451B/F/TAF | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 16 est. | Mar 2028 |
| PROPELImplementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV PreventionNCT07473778Lenacapavir Injection | — | Not yet scored | OngoingRecruiting | 3,000 est. | Apr 2028 |
| Study of GS-5319 Given Alone or in Combination in Adults With Solid TumorsNCT07128303GS-5319 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 476 est. | May 2028 |
| Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid TumorsNCT06532565GS-2121 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 154 est. | Jun 2028 |
| A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerNCT06926920Sacituzumab Govitecan-hziy (SG) | Phase 1 | Locked · track to reveal | OngoingRecruiting | 100 est. | Jun 2028 |
| STAR-121Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerNCT05502237Zimberelimab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,021 est. | Jun 2028 |
| iMMagine-3A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaNCT06413498Anitocabtagene Autoleucel | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 452 est. | Jul 2028 |
| ASCENT-03Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299Sacituzumab Govitecan-hziy | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 623 est. | Jul 2028 |
| Study of GS-0201 Alone and in Combination in Participants With Advanced Solid TumorsNCT06167317GS-0201 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 278 est. | Sept 2028 |
| PURPOSE 365Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)NCT07047716Lenacapavir Injection | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 339 est. | Sept 2028 |
| Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)NCT03301506Seladelpar 5 mg Capsule | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 340 est. | Nov 2028 |
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerNCT07527858Denikitug | Phase 2 | Locked · track to reveal | OngoingRecruiting | 170 est. | Dec 2028 |
| Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid TumorsNCT05007782Denikitug | Phase 1 | Locked · track to reveal | OngoingRecruiting | 416 est. | Dec 2028 |
| Study of GS-2426 in Participants With Advanced Solid TumorsNCT07601243GS-2426 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 174 est. | Jan 2029 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyNCT07682961Lenacapavir | Phase 3 | Not yet scored | OngoingRecruiting | 590 est. | Mar 2029 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensNCT07683000Lenacapavir | Phase 3 | Not yet scored | OngoingRecruiting | 590 est. | Mar 2029 |
| A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesNCT07304154KITE-363 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 52 est. | Jun 2029 |
| ASCENT-GYN-01Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)NCT06486441Sacituzumab govitecan-hziy | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 640 est. | Jun 2029 |
| A Study of KITE-363 in Participants With Refractory Autoimmune DiseasesNCT07038447KITE-363 | Phase 1 | Locked · track to reveal | OngoingEnrolling by invitation | 52 est. | Jul 2029 |
| Study of GS-0415 and How It Works in People With HIVNCT07719491GS-0415 | Phase 1 | Not yet scored | OngoingRecruiting | 112 est. | Aug 2029 |
| A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid TumorsNCT07703878GS-1206 | Phase 1 | Not yet scored | OngoingRecruiting | 302 est. | Sept 2029 |
| VELOCITY-LungStudy of Novel Treatment Combinations in Patients With Lung CancerNCT05633667Zimberelimab (ZIM) | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 192 est. | Sept 2029 |
| EVOKE-SCLC-04Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834Sacituzumab Govitecan (SG) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 695 est. | Oct 2029 |
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasNCT07546812Denikitug | Phase 2 | Locked · track to reveal | OngoingRecruiting | 120 est. | Jan 2030 |
| Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta VirusNCT07096193GS-4321 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 200 est. | Jan 2030 |
| PALISADES-1Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell LymphomaNCT04989803Cyclophosphamide | Phase 1 | Locked · track to reveal | OngoingRecruiting | 247 est. | Feb 2030 |
| TROPHY U-01Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadNCT03547973Sacituzumab Govitecan-hziy | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 502 est. | Apr 2030 |
| Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1NCT06532656Lenacapavir | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 75 est. | Jul 2030 |
| AFFIRMSeladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisNCT06051617Seladelpar | Phase 3 | Locked · track to reveal | OngoingRecruiting | 402 est. | Aug 2030 |
| Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentNCT07708727GS-3242 Tablet | Phase 2 | Not yet scored | OngoingRecruiting | 700 est. | Oct 2030 |
| ZUMA-23Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell LymphomaNCT05605899Axicabtagene Ciloleucel | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 300 est. | Mar 2031 |